Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Development of a humanized mouse model with functional human materno-fetal interface immunity
Shuai Dong, … , Yong-Guang Yang, Zheng Hu
Shuai Dong, … , Yong-Guang Yang, Zheng Hu
Published October 22, 2024
Citation Information: JCI Insight. 2024;9(20):e176527. https://doi.org/10.1172/jci.insight.176527.
View: Text | PDF
Research Article Immunology Reproductive biology

Development of a humanized mouse model with functional human materno-fetal interface immunity

  • Text
  • PDF
Abstract

Materno-fetal immunity possesses specialized characteristics to ensure pathogen clearance while maintaining tolerance to the semiallogeneic fetus. Most of our understanding on human materno-fetal immunity is based on conventional rodent models that may not precisely represent human immunological processes owing to the huge evolutionary divergence. Herein, we developed a pregnant human immune system (HIS) mouse model through busulfan preconditioning, which hosts multilineage human immune subset reconstitution at the materno-fetal interface. Human materno-fetal immunity exhibits a tolerogenic feature at the midgestation stage (embryonic day [E] 14.5), and human immune regulatory subsets were detected in the decidua. However, the immune system switches to an inflammatory profile at the late gestation stage (E19). A cell–cell interaction network contributing to the alternations in the human materno-fetal immune atmosphere was revealed based on single-cell RNA-Seq analysis, wherein human macrophages played crucial roles by secreting several immune regulatory mediators. Furthermore, depletion of Treg cells at E2.5 and E5.5 resulted in severe inflammation and fetus rejection. Collectively, these results demonstrate that the pregnant HIS mouse model permits the development of functional human materno-fetal immunity and offers a tool for human materno-fetal immunity investigation to facilitate drug discovery for reproductive disorders.

Authors

Shuai Dong, Cong Fu, Chang Shu, Min Xie, Yan Li, Jun Zou, Yi-Zi Meng, Peng Xu, Yan-Hong Shan, Hui-Min Tian, Jin He, Yong-Guang Yang, Zheng Hu

×

Figure 2

Human immune subset composition in pregnant HIS mice at E14.5.

Options: View larger image (or click on image) Download as PowerPoint
Human immune subset composition in pregnant HIS mice at E14.5.
HIS mice ...
HIS mice (n = 10) made by the busulfan protocol were mated with BALB/c males and euthanized at E14.5 for analysis. Summarized data about the chimerism (mean ± SEM) of human lymphohematopoietic cells (A) (%huCD45+/[%hCD45+ + %mCD45+]) and ratios (B) of CD3+ T cells, CD20+ B cells, CD14+ macrophages, and CD56+ NK cells within human CD45+ cells in PBMCs, spleen, and decidua were shown. (C) Summarized results (mean ± SEM; n = 7) of the percentages of CD49a+ and CD49a+CD103+ tissue-resident NK cells in human CD56+CD16– NK cells. (D) Summarized results (mean ± SEM; n = 7) of the percentages of CD56+CD16– NK cells and representative flow cytometric profiles were shown. (E–G) Summarized results (mean ± SEM; n = 7) of the percentages of CD14+HLA-DR+ human macrophages (E), CD206+ M2 macrophages (F), and CD80+ M1 macrophages (G) were shown. (H) Summarized results (mean ± SEM; left; n = 5) and representative flow cytometry (FCM) profiles (right) of the ratios of Treg cells. (I) Immunohistochemical (IHC) examination of human CD45+ lymphohematopoietic cells (left) and CD4+ T cells (right) in decidua. D, decidua. Statistical differences were determined with 1-way ANOVA for multiple-variable comparisons (A and C–H).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts